Clinical application for treatment of lymphoma in Class 1 of East Sunshine Drug

Medical Network May 14 hearing May 12, East Sunshine drug class of drugs in clinical application HEC89736PTSA · 0.5H2O film won the CDE contractor acceptance, acceptance number CXHL2000195, CXHL2000196, CXHL2000197It is understood within the meter network, HEC89736PTSA · 0.5H2O of PI3Kδ inhibitor developed clinical indications of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)Currently No PI3Kδ inhibitors target marketHEC89736PTSA · 0.5H2O East Sunshine is self-developed synthetic drugs highly selective PI3Kδ inhibitor for oral, develop clinical indications of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) is a class of progressive lymphocytosis, lymphadenopathy and splenomegaly characterized by mature B lymphocytes in the blood < br />PI3Kδ inhibitor of B-cell lymphoma, CLL / SLL have a very good therapeutic effect, domestic PI3Kδ inhibitor No target marketAccording to themeters network statistics, 2020 East Sunshine Pharmaceutical paragraph 3 has filed a class of drugs in clinical application, respectively hydrochloride Iraq pirfenidone tablets, p-toluenesulfonic acid Groninger imatinib capsules, HEC89736PTSA · 0.5H2O piece2020 East Sunshine drug has declared a class of drugs in clinicalp-toluenesulfonic acid Groninger imatinib capsule is a novel small molecule multi-targeted tyrosine kinase inhibitors, can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit kinase and the like, and has anti-angiogenesis effect of inhibition of tumor growthIraq pirfenidone are a class of drugs developed by the East Sunshine drugs for the treatment of idiopathic pulmonary fibrosis (IPF), and in August 2017 by FDA orphan drug qualificationHydrochloric acid Iraq pirfenidone capsules in the country has completed Phase I clinical hydrochloride tablets Iraq pirfenidone clinical application in 2020 18 February won CDE contractors, to secure the acquiescence of clinical April 2020Source: CDE, the network database m